---
title: "Jefferies Sticks to Its Buy Rating for Kodiak Sciences (KOD)"
description: "According to TipRanks, Raycroft is a 4-star analyst with an average return of 10.7% and a 42.35% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Kodiak Sciences, BioCry"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262895516.md"
published_at: "2025-10-27T12:05:52.000Z"
---

# Jefferies Sticks to Its Buy Rating for Kodiak Sciences (KOD)

> According to TipRanks, Raycroft is a 4-star analyst with an average return of 10.7% and a 42.35% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Kodiak Sciences, BioCryst, and Travere Therapeutics. Kodiak Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $20.33, which is an 8.77% upside from current levels. In a report released on October 25, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $40.00 price target.

According to TipRanks, Raycroft is a 4-star analyst with an average return of 10.7% and a 42.35% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Kodiak Sciences, BioCryst, and Travere Therapeutics.

Kodiak Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $20.33, which is an 8.77% upside from current levels. In a report released on October 25, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $40.00 price target.

### Related Stocks

- [KOD.US - Kodiak Sciences](https://longbridge.com/en/quote/KOD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSA Capital Partners LLP 出售了 76,735 股 Kodiak Sciences 公司的股票，代码为$KOD | GSA Capital Partners LLP 已将其在 Kodiak Sciences Inc. 的股份减少了 46.7%，在第三季度出售了 76,735 股，剩余 87,697 股，估值约为 144 万美元。其他机构投资者也调整了他们 | [Link](https://longbridge.com/en/news/276216383.md) |
| Kodiak Sciences Inc. (NASDAQ:KOD) 的空头头寸更新 | Kodiak Sciences Inc.（纳斯达克代码：KOD）在空头头寸方面经历了显著增长，截至 12 月 31 日，空头头寸增加了 34.5%，达到 6,287,793 股。这代表了公司已售空股份的 21.9%，基于每日平均交易量 1, | [Link](https://longbridge.com/en/news/272902132.md) |
| 双威医疗保健委任六家投行担任上市承销商 \| 联合早报网 | 双威医疗保健（Sunway Healthcare）已委任六家投资银行作为首次公开售股（IPO）的承销商，计划在马来西亚上市，预计集资超过 30 亿令吉，估值将超过 150 亿令吉。承销商包括马来亚、艾芬黄氏、联昌国际、兴业、肯纳格及大马投资 | [Link](https://longbridge.com/en/news/275451558.md) |
| 瑞穗证券发布了关于 LeonaBio（LONA）的正面报告 | 瑞穗证券分析师 Graig Suvannavejh 将 LeonaBio (LONA) 的评级上调至买入，目标价为 10.00 美元。Suvannavejh 专注于医疗保健领域，推荐股票的平均回报率为 20.3%，成功率为 50.00%。此 | [Link](https://longbridge.com/en/news/276278570.md) |
| Palvella Therapeutics (PVLA) 获得了 Craig-Hallum 的买入评级 | 在最近的一份报告中，Craig-Hallum 分析师 Albert Lowe 对 Palvella Therapeutics (PVLA) 维持了买入评级，目标价为 205.00 美元。Lowe 是一位四星级分析师，平均回报率为 8.4%， | [Link](https://longbridge.com/en/news/276240277.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.